Inventor · disambiguated record
Liansheng Su
Also filed as: SU LIANSHENG
4 granted patents·3 pending applications·4 citations·filing 2011–2024
60Inventor score
Top patents by PatentIndex Score
7 records- 0175US8697739B2Bicyclic acetyl-CoA carboxylase inhibitors and uses thereofBARNES DAVID WENINGER·Filed 2011·Granted Apr 15, 2014·4 cites·23 claims
- 0274US12129246B1Hydroquinazoline derivatives for the treatment of a disease or disorderNOVARTIS AG·Filed 2024·Granted Oct 29, 2024·0 cites·30 claims
- 0361US11813306B2Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disordersNOVARTIS AG·Filed 2021·Granted Nov 14, 2023·0 cites·20 claims
- 0459US11026993B2Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disordersNOVARTIS AG·Filed 2019·Granted Jun 8, 2021·0 cites·33 claims
- 0559US2025145600A12-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesityNOVARTIS AG·Filed 2023·Application pending·0 cites
- 0654US2024182456A12-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesityNOVARTIS AG·Filed 2022·Application pending·0 cites
- 0746US2023089867A1Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorderNOVARTIS AG·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Liansheng Su files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →